252 related articles for article (PubMed ID: 28937020)
21. Clinical outcome and molecular landscape of patients with ARID1A-loss gastric cancer.
Sun M; Gu Y; Fang H; Shao F; Lin C; Zhang H; Li H; He H; Li R; Wang J; Liu H; Xu J
Cancer Sci; 2024 Mar; 115(3):905-915. PubMed ID: 38148578
[TBL] [Abstract][Full Text] [Related]
22. Expression and significance of EBV, ARID1A and PIK3CA in gastric carcinoma.
Zhou H; Tan S; Li H; Lin X
Mol Med Rep; 2019 Mar; 19(3):2125-2136. PubMed ID: 30747208
[TBL] [Abstract][Full Text] [Related]
23. Frameshift Mutations in the Mononucleotide Repeats of TAF1 and TAF1L Genes in Gastric and Colorectal Cancers with Regional Heterogeneity.
Oh HR; An CH; Yoo NJ; Lee SH
Pathol Oncol Res; 2017 Jan; 23(1):125-130. PubMed ID: 27571988
[TBL] [Abstract][Full Text] [Related]
24. Altered ARID1A expression in colorectal cancer.
Erfani M; Hosseini SV; Mokhtari M; Zamani M; Tahmasebi K; Alizadeh Naini M; Taghavi A; Carethers JM; Koi M; Brim H; Mokarram P; Ashktorab H
BMC Cancer; 2020 Apr; 20(1):350. PubMed ID: 32334542
[TBL] [Abstract][Full Text] [Related]
25. Somatic frameshift mutations of bone morphogenic protein receptor 2 gene in gastric and colorectal cancers with microsatellite instability.
Park SW; Hur SY; Yoo NJ; Lee SH
APMIS; 2010 Nov; 118(11):824-9. PubMed ID: 20955454
[TBL] [Abstract][Full Text] [Related]
26. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer.
Wang K; Kan J; Yuen ST; Shi ST; Chu KM; Law S; Chan TL; Kan Z; Chan AS; Tsui WY; Lee SP; Ho SL; Chan AK; Cheng GH; Roberts PC; Rejto PA; Gibson NW; Pocalyko DJ; Mao M; Xu J; Leung SY
Nat Genet; 2011 Oct; 43(12):1219-23. PubMed ID: 22037554
[TBL] [Abstract][Full Text] [Related]
27. Decreased expression of the ARID1A gene is associated with poor prognosis in primary gastric cancer.
Wang DD; Chen YB; Pan K; Wang W; Chen SP; Chen JG; Zhao JJ; Lv L; Pan QZ; Li YQ; Wang QJ; Huang LX; Ke ML; He J; Xia JC
PLoS One; 2012; 7(7):e40364. PubMed ID: 22808142
[TBL] [Abstract][Full Text] [Related]
28. Frameshift mutations of axon guidance genes ROBO1 and ROBO2 in gastric and colorectal cancers with microsatellite instability.
Je EM; Gwak M; Oh H; Choi MR; Choi YJ; Lee SH; Yoo NJ
Pathology; 2013 Dec; 45(7):645-50. PubMed ID: 24247621
[TBL] [Abstract][Full Text] [Related]
29. EBV infection and MSI status significantly influence the clinical outcomes of gastric cancer patients.
Shen H; Zhong M; Wang W; Liao P; Yin X; Rotroff D; Knepper TC; Mcleod HL; Zhou C; Xie S; Li W; Xu B; He Y
Clin Chim Acta; 2017 Aug; 471():216-221. PubMed ID: 28601671
[TBL] [Abstract][Full Text] [Related]
30. Chromatin remodeling gene AT-rich interactive domain-containing protein 1A suppresses gastric cancer cell proliferation by targeting PIK3CA and PDK1.
Zhang Q; Yan HB; Wang J; Cui SJ; Wang XQ; Jiang YH; Feng L; Yang PY; Liu F
Oncotarget; 2016 Jul; 7(29):46127-46141. PubMed ID: 27323812
[TBL] [Abstract][Full Text] [Related]
31. Intratumoral heterogeneity for inactivating frameshift mutation of CUX1 and SIRT1 genes in gastric and colorectal cancers.
Jo YS; Kim MS; Yoo NJ; Lee SH
Pol J Pathol; 2017; 68(3):258-260. PubMed ID: 29363918
[TBL] [Abstract][Full Text] [Related]
32. Implication of ARID1A Undercurrents and PDL1, TP53 Overexpression in Advanced Gastric Cancer.
Qadir J; Majid S; Khan MS; Rashid F; Wani MD; Bhat SA
Pathol Oncol Res; 2021; 27():1609826. PubMed ID: 34924820
[TBL] [Abstract][Full Text] [Related]
33. Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis.
Luchini C; Veronese N; Solmi M; Cho H; Kim JH; Chou A; Gill AJ; Faraj SF; Chaux A; Netto GJ; Nakayama K; Kyo S; Lee SY; Kim DW; Yousef GM; Scorilas A; Nelson GS; Köbel M; Kalloger SE; Schaeffer DF; Yan HB; Liu F; Yokoyama Y; Zhang X; Pang D; Lichner Z; Sergi G; Manzato E; Capelli P; Wood LD; Scarpa A; Correll CU
Oncotarget; 2015 Nov; 6(36):39088-97. PubMed ID: 26384299
[TBL] [Abstract][Full Text] [Related]
34. Mutational and expressional analysis of RFC3, a clamp loader in DNA replication, in gastric and colorectal cancers.
Kim YR; Song SY; Kim SS; An CH; Lee SH; Yoo NJ
Hum Pathol; 2010 Oct; 41(10):1431-7. PubMed ID: 20573375
[TBL] [Abstract][Full Text] [Related]
35. ARID1A facilitates KRAS signaling-regulated enhancer activity in an AP1-dependent manner in colorectal cancer cells.
Sen M; Wang X; Hamdan FH; Rapp J; Eggert J; Kosinsky RL; Wegwitz F; Kutschat AP; Younesi FS; Gaedcke J; Grade M; Hessmann E; Papantonis A; Strӧbel P; Johnsen SA
Clin Epigenetics; 2019 Jun; 11(1):92. PubMed ID: 31217031
[TBL] [Abstract][Full Text] [Related]
36. Associations Between Loss of ARID1A Expression and Clinicopathologic and Genetic Variables in T1 Early Colorectal Cancer.
Kishida Y; Oishi T; Sugino T; Shiomi A; Urakami K; Kusuhara M; Yamaguchi K; Kitagawa Y; Ono H
Am J Clin Pathol; 2019 Sep; 152(4):463-470. PubMed ID: 31263894
[TBL] [Abstract][Full Text] [Related]
37. Loss of ARID1A expression is associated with poor prognosis in patients with gastric cancer.
Zhu YP; Sheng LL; Wu J; Yang M; Cheng XF; Wu NN; Ye XB; Cai J; Wang L; Shen Q; Wu JQ
Hum Pathol; 2018 Aug; 78():28-35. PubMed ID: 29689245
[TBL] [Abstract][Full Text] [Related]
38. ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer.
Mehrvarz Sarshekeh A; Alshenaifi J; Roszik J; Manyam GC; Advani SM; Katkhuda R; Verma A; Lam M; Willis J; Shen JP; Morris J; Davis JS; Loree JM; Lee HM; Ajani JA; Maru DM; Overman MJ; Kopetz S
Clin Cancer Res; 2021 Mar; 27(6):1663-1670. PubMed ID: 33414133
[TBL] [Abstract][Full Text] [Related]
39. Loss of ARID1A expression is associated with systemic inflammation markers and has important prognostic significance in gastric cancer.
Wang X; Che K; Shi T; Liu Q; Xu X; Wu H; Yu L; Liu B; Wei J
J Cancer Res Clin Oncol; 2022 Jul; 148(7):1583-1595. PubMed ID: 35294647
[TBL] [Abstract][Full Text] [Related]
40. ARID1A loss-of-function induces CpG island methylator phenotype.
Yamada H; Takeshima H; Fujiki R; Yamashita S; Sekine S; Ando T; Hattori N; Okabe A; Yoshikawa T; Obama K; Katai H; Kaneda A; Ushijima T
Cancer Lett; 2022 Apr; 532():215587. PubMed ID: 35131383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
